Document Detail


Clinical experience with sotalol in the treatment of cardiac arrhythmias.
MedLine Citation:
PMID:  7923303     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment of cardiac arrhythmias has changed over the past several years, as concerns have grown about proarrhythmias and increased mortality associated with certain antiarrhythmic agents. Sotalol, a unique racemic compound with both Class II (beta-blocking) and Class III (repolarization-prolonging) properties, effectively controls life-threatening arrhythmias and has a favorable safety profile, especially when compared with traditional antiarrhythmic drugs. A review of clinical trials demonstrates that sotalol is an effective treatment for premature ventricular complexes, ventricular tachycardia, and ventricular fibrillation. Moreover, it significantly reduces cardiac and all-cause mortality in these patient populations. Although sotalol currently is approved in the United States only for the treatment of life-threatening ventricular arrhythmias, it also is active against several supraventricular arrhythmias. Sotalol is safe and generally well tolerated; most of the adverse effects experienced with its use are related to its beta-blocking activity. However, sotalol has been associated with life-threatening proarrhythmias, including torsades de pointes, but the incidence of this adverse effect is low. Unlike pure Class II agents, sotalol usually is well tolerated in patients with mild-to-moderate left ventricular dysfunction and rarely causes new or worsening congestive heart failure. Sotalol represents an advance in the treatment and prevention of symptomatic ventricular arrhythmias and appears to be a reasonable first-line choice when the arrhythmia is life threatening.
Authors:
H L Kirschenbaum; J M Rosenberg
Related Documents :
3311793 - Mechanisms for cardiac arrhythmias.
22465463 - Automatic left ventricle segmentation in cardiac mri using topological stable-state thr...
139103 - Interventricular septal motion and left ventricular function after coronary bypass surg...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical therapeutics     Volume:  16     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:    1994 May-Jun
Date Detail:
Created Date:  1994-11-23     Completed Date:  1994-11-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  346-64     Citation Subset:  IM    
Affiliation:
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arrhythmias, Cardiac / drug therapy*
Humans
Sotalol / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
3930-20-9/Sotalol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibitory effects of nicorandil on sympathetic coronary vasoconstriction.
Next Document:  A review of clinical trials comparing HMG-CoA reductase inhibitors.